The earnings call highlighted MindMed's strong financial position and progress towards Phase III trials, while also acknowledging rising R&D expenses and a net loss. The sentiment leans towards positive due to the company's strong cash reserves and clear roadmap for advancing clinical trials.

Company Guidance

During the Mind Medicine (MNMD) Q3 2024 earnings call, the company provided detailed guidance on their Phase III clinical programs for MM-120, an orally disintegrating tablet aimed at treating generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company is set to initiate the VOYAGE study for GAD by the end of 2024, followed by the PANORAMA study for GAD and the EMERGE study for MDD in the first half of 2025. These studies will address a significant unmet medical need, affecting approximately 51 million adults in the U.S. With 200 participants anticipated for VOYAGE and 240 for PANORAMA, both studies will leverage a 12-week double-blind, placebo-controlled design followed by a 40-week extension. The company reported a net loss of $13.7 million for Q3 2024, a decrease from $17.9 million in Q3 2023, and ended the quarter with $295.3 million in cash, expected to fund operations into 2027.

Strong Cash Position

MindMed ended the quarter with $295.3 million in cash and cash equivalents, compared to $99.7 million at the end of 2023, sufficient to fund operations into 2027.

Phase III Trials Progress

The company is on track to initiate multiple Phase III studies for MM-120-ODT for GAD and MDD, with the first study, VOYAGE, set to start by the end of 2024.

Clinical Trial Design Strategy

MindMed has implemented rigorous trial designs to address methodological challenges, such as functional unblinding, with strategies like central raters and additional control arms.

R&D Advancements

R&D expenses increased to $17.2 million, reflecting advancement into pivotal studies and increased personnel costs. The company plans to ramp up R&D expenses further in 2025.

---

Mind Medicine (MNMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MNMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 08, 2025	2024 (Q4)	-0.29 / -	-1.14	―	―	―
Nov 07, 2024	2024 (Q3)	-0.28 / -0.18	-0.45	60.00% (+0.27)	―
Aug 13, 2024	2024 (Q2)	-0.33 / -0.08	-0.76	89.47% (+0.68)	―
May 08, 2024	2024 (Q1)	-0.53 / -1.14	-0.65	-75.38% (-0.49)	―
Feb 28, 2024	2023 (Q4)	-0.46 / -0.58	-0.13	-346.15% (-0.45)	―
Nov 02, 2023	2023 (Q3)	-0.65 / -0.45	-0.56	19.64% (+0.11)	―
Aug 03, 2023	2023 (Q2)	-0.53 / -0.76	-0.6	-26.67% (-0.16)	―
May 04, 2023	2023 (Q1)	-0.42 / -0.65	-0.6	-8.33% (-0.05)	―	―
Mar 09, 2023	2022 (Q4)	-0.49 / -0.13	-0.6	78.33% (+0.47)	―	―
Nov 10, 2022	2022 (Q3)	-0.59 / -0.56	-0.9	37.78% (+0.34)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

MNMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 07, 2024	$7.52	$8.49	+12.90%
Aug 13, 2024	$6.85	$6.59	-3.80%
May 08, 2024	$9.61	$9.12	-5.10%
Feb 28, 2024	$5.56	$5.35	-3.78%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---